Health
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology
Peer-reviewed publication in prominent nephrology journal reinforces clinical differentiation of Vafseo® (vadadustat) in dialysis-dependent CKD anemiaCAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the publication of a post-hoc win statistics analysis of all-cause mortality and hospitalization from its global Phase 3 INNO2VATE progra
About this update from Akebia Therapeutics, Inc.
[{"type":"image","alt":"Akebia Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Akebia Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/865d2292021f9ae78a76043efeea8849"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qSd0MCVi23P15eWkfi6nEw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MQ--/https://media.zenfs.com/en/globenewswire.com/865d2292021f9ae78a76043efeea8849","width":300,"height":122}},"lazy":false},{"type":"text","content":"Peer-reviewed publication in prominent nephrology journal reinforces clinical differentiation of Vafseo® (vadadustat) in dialysis-dependent CKD anemia","length":150,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the publication of a post-hoc win statistics analysis of all-cause mortality and hospitalization from its global Phase 3 INNO2VATE program in the Journal of the American Society of Nephrology (JASN), a leading, high-impact, peer-reviewed journal in nephrology.","length":473,"tagName":"p"},{"type":"text","content":"“The win statistics analysis highlighted favorable outcomes and potential clinical differentiation for Vafseo that we believe are central to ensure informed clinical decision-making for nephrologists and other care providers,” said Dr. Steven Burke, Chief R&D and Medical Officer at Akebia. “As we work toward our goal to make Vafseo standard of care in patients with anemia due to CKD receiving dialysis, we believe publication in JASN further validates the strength of the vadadustat dataset and supports strong engagement with prescribers, providers and payors.”","length":569,"tagName":"p"},{"type":"text","content":"As reported in the Research Letter titled, “Comparing Vadadustat and Darbepoetin in Maintenance Dialysis with chronic kidney disease (CKD)-Related Anemia,” vadadustat demonstrated a statistically significant improvement relative to the erythropoiesis-stimulating agent (ESA), darbepoetin alfa, on a hierarchical composite endpoint of all-cause mortality and hospitalization in patients with anemia due to chronic kidney disease receiving dialysis, which we...